These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28993963)

  • 1. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms.
    Cornu C; Mercier C; Ginhoux T; Masson S; Mouchet J; Nony P; Kassai B; Laudy V; Berquin P; Franc N; Le Heuzey MF; Desombre H; Revol O
    Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):377-384. PubMed ID: 28993963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children.
    Carucci S; Romaniello R; Demuru G; Curatolo P; Grelloni C; Masi G; Liboni F; Mereu A; Contu P; Lamberti M; Gagliano A; Zuddas A
    Eur Arch Psychiatry Clin Neurosci; 2022 Dec; 272(8):1453-1467. PubMed ID: 35672606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder.
    Bos DJ; Oranje B; Veerhoek ES; Van Diepen RM; Weusten JM; Demmelmair H; Koletzko B; de Sain-van der Velden MG; Eilander A; Hoeksma M; Durston S
    Neuropsychopharmacology; 2015 Sep; 40(10):2298-306. PubMed ID: 25790022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Crippa A; Tesei A; Sangiorgio F; Salandi A; Trabattoni S; Grazioli S; Agostoni C; Molteni M; Nobile M
    Eur Child Adolesc Psychiatry; 2019 Apr; 28(4):571-583. PubMed ID: 30246216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of omega-3 supplementation in reducing ADHD associated symptoms in children as measured by the Conners' rating scales: A systematic review of randomized controlled trials.
    Abdullah M; Jowett B; Whittaker PJ; Patterson L
    J Psychiatr Res; 2019 Mar; 110():64-73. PubMed ID: 30594823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial.
    Kean JD; Sarris J; Scholey A; Silberstein R; Downey LA; Stough C
    Psychopharmacology (Berl); 2017 Feb; 234(3):403-420. PubMed ID: 27921139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial investigating the effects of PCSO-524, a patented oil extract of the New Zealand green lipped mussel (Perna canaliculus), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066.
    Kean JD; Camfield D; Sarris J; Kras M; Silberstein R; Scholey A; Stough C
    Nutr J; 2013 Jul; 12():100. PubMed ID: 23866813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial.
    Rheims S; Herbillon V; Gaillard S; Mercier C; Villeuve N; Villéga F; Cances C; Castelnau P; Napuri S; de Saint-Martin A; Auvin S; Nguyen The Tich S; Berquin P; de Bellecize J; Milh M; Roy P; Arzimanoglou A; Bodennec J; Bezin L; Kassai B;
    Epilepsia Open; 2024 Apr; 9(2):582-591. PubMed ID: 38173190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial.
    Milte CM; Parletta N; Buckley JD; Coates AM; Young RM; Howe PR
    Nutrition; 2012 Jun; 28(6):670-7. PubMed ID: 22541055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Erythrocyte Eicosapentaenoic Acid and Docosahexaenoic Acid Are Associated With Improved Attention and Behavior in Children With ADHD in a Randomized Controlled Three-Way Crossover Trial.
    Milte CM; Parletta N; Buckley JD; Coates AM; Young RM; Howe PR
    J Atten Disord; 2015 Nov; 19(11):954-64. PubMed ID: 24214970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents.
    Johnson M; Månsson JE; Ostlund S; Fransson G; Areskoug B; Hjalmarsson K; Landgren M; Kadesjö B; Gillberg C
    Atten Defic Hyperact Disord; 2012 Dec; 4(4):199-204. PubMed ID: 22753087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial.
    Widenhorn-Müller K; Schwanda S; Scholz E; Spitzer M; Bode H
    Prostaglandins Leukot Essent Fatty Acids; 2014; 91(1-2):49-60. PubMed ID: 24958525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls.
    Parletta N; Niyonsenga T; Duff J
    PLoS One; 2016; 11(5):e0156432. PubMed ID: 27232999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder.
    Voigt RG; Llorente AM; Jensen CL; Fraley JK; Berretta MC; Heird WC
    J Pediatr; 2001 Aug; 139(2):189-96. PubMed ID: 11487742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension.
    Manor I; Magen A; Keidar D; Rosen S; Tasker H; Cohen T; Richter Y; Zaaroor-Regev D; Manor Y; Weizman A
    Eur Psychiatry; 2012 Jul; 27(5):335-42. PubMed ID: 21807480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
    Jain R; Segal S; Kollins SH; Khayrallah M
    J Am Acad Child Adolesc Psychiatry; 2011 Feb; 50(2):171-9. PubMed ID: 21241954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents.
    Johnson M; Ostlund S; Fransson G; Kadesjö B; Gillberg C
    J Atten Disord; 2009 Mar; 12(5):394-401. PubMed ID: 18448859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.